The emerging concept of cardiovascular-kidney-metabolic syndrome recognizes how diabetes, heart disease, and kidney dysfunction interconnect in ways that traditional single-organ approaches often miss. This comprehensive view matters because optimal drug selection in early diabetes could prevent the cascade of complications that typically develops over decades, potentially transforming long-term health trajectories for millions of adults.
A retrospective analysis of 18,467 newly diagnosed diabetic patients revealed striking differences in organ protection across eight major diabetes medication classes. SGLT2 inhibitors demonstrated exceptional kidney preservation, with other medications showing 3.6 to 19-fold higher rates of end-stage renal disease progression. The mortality advantage was even more pronounced, with alternative therapies associated with 5.8 to 67-fold higher death rates compared to SGLT2 inhibitor treatment. Insulin therapy specifically increased stroke risk by 65% and heart attack risk by 147%, while most other diabetes medications provided cardiovascular protection versus no treatment.
These findings illuminate a critical treatment hierarchy that challenges conventional diabetes management approaches. While multiple medication classes offer cardiovascular benefits, the renal and survival advantages of SGLT2 inhibitors appear unmatched in early disease stages. The particularly pronounced kidney protection in younger and obese patients suggests these drugs may interrupt fundamental metabolic pathways before irreversible damage occurs. However, this real-world evidence from Taiwan requires validation across diverse populations, and the observational design cannot definitively establish causation. The results support prioritizing SGLT2 inhibitors as first-line therapy when appropriate, representing a paradigm shift toward comprehensive cardiorenal protection rather than isolated glucose control in diabetes management.